Allogene Therapeutics, Inc. (ALLO)
After hours:
| Previous close | 18.75 |
| Open | 18.55 |
| Bid | 0.00 x 1400 |
| Ask | 0.00 x 1000 |
| Day's range | 17.86 - 19.11 |
| 52-week range | 12.90 - 39.12 |
| Volume | |
| Avg. volume | 1,942,277 |
| Market cap | 2.695B |
| Beta (5Y monthly) | 0.76 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2021 American Society of Hematology Annual Meeting
Conference Call and Webcast Scheduled for Monday, December 13, 2021 at 1:30 PM PT/4:30 PM ET SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management will host a conference call to review data to be presented at the American Society of Hematology Annual Meeting from the ALPHA and ALPHA2 Phase 1 t
- GlobeNewswire
Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in five upcoming virtual investor conferences. Cowen's 5th Annual IO Next SummitMonday, November 15, 20218:45 AM PT/11:45 AM ET Stifel 2021 Virtual Healthcare ConferenceTuesday, November 16, 202111:00 AM PT/2:00 PM ET J
- GlobeNewswire
Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update
New Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T™ Trials to be Presented at the 63rd Annual Meeting of the American Society of Hematology ALPHA2 Study Abstract Selected for Oral Presentation Highlights the Benefits of Consolidation Dosing with ALLO-501A in Patients with Relapsed/Refractory Large B Cell LymphomaALPHA Study Abstract Selected for Poster Presentation Continues to Show Durability of Responses to ALLO-501 in Patients with Non-Hodgkin LymphomaUNIVERSAL Study Abstract Se
